fbpx

Building the Vectra Story: News from EULAR 2017 (Part 2)

Hello again! As Senior Medical Science Liaison in the Medical Affairs department at Crescendo Bioscience, one of my responsibilities is to attend medical meetings, where, in addition to presenting some of our latest data, I meet with international key opinion leaders and stay abreast of the science around RA. In my last post, I brought you up to speed on the Vectra studies that were presented the European League Against Rheumatism (EULAR) Annual Congress, which took place this year in Madrid, from June 14 – 17, with more than 16,000 people from 120 countries in attendance. In this post, I’d like to share some additional research I gathered while attending this year’s EULAR meeting.

In addition to supporting the presentation of our studies and attending various meetings, I made sure that I had a chance to catch up on other news in the field by attending different scientific sessions. One of the big topics at this year’s meeting was stomach bacteria and its role in the development of autoimmune diseases, which potentially represents a new approach to the treatment of autoimmune disease.

There was also an interesting debate in one session about whether newer sensitive measures, such as US, MRI, and Vectra, should be included in the definition of RA remission. While the discussion included both pros and cons, there was an overall feeling that there is a role for these measures, but that it is still early.

Another discussion was around the U.S. Food and Drug Administration’s (FDA) willingness to consider MRI as an endpoint for trials in RA. MRI can detect changes in joints earlier compared to x-ray. For patients, this translates into the possibility that studies might take place with smaller numbers of patients on shorter time frames, potentially resulting in new medicines getting to patients faster.

Crescendo Bioscience activities

While on site, my colleagues and I had the chance to meet with investigators from around the world who are involved in research related to Vectra. At our bi-annual Scientific Advisory Board meeting, there was a lot of discussion and excitement about how we hope to develop Vectra even further. We also had interesting meetings with several pharmaceutical companies and met with several of our [academic] partners about opportunities for future collaborations.

Along with the American College of Rheumatology (ACR) annual meeting, which will take place November 3-8 in San Diego, EULAR is one of the most important international medical meetings on rheumatic diseases and also includes musculoskeletal diseases. I love going every year and feel so inspired by the advances being made across the field for RA patients.

Full abstracts of these and all EULAR presentations are available at this link.

EULAR

Recent Posts

My Doctor Said I Have RA but I’m Not That Old!

This month is National Arthritis Awareness Month. Whether you’re newly diagnosed or are an RA veteran—please leave a comment about what resonates with you, what your experience with RA has been or tips and advice to share with the RA community. We want to hear from you! “I was only…
Read more

Pain & RA Disease Activity: When They Don’t Align

Rheumatoid Arthritis & Pain Management
Pain can be a part of life with RA. Even if your therapy is working and you’re in remission, you can still experience pain: More than 10% of people with RA who had achieved one standard definition of disease remission still reported persistent pain in one study¹.  Why Pain Matters…
Read more

Telemedicine Appointments

76
Many doctor offices have moved to telehealth visits right now, to minimize the risk of potential exposure to COVID-19. The telehealth visit allows your provider to talk to you about your disease and symptoms just as he/she would in an in-office appointment.  Maybe you’ve never had to do a telehealth…
Read more

Linda’s Patient Journey – March 2020 Autoimmune Month

Linda's RA Journey
Week 1: Leading up to diagnosis… Sitting in the doctor’s exam room, I wasn’t expecting to hear the words my healthcare provider said, “You have rheumatoid arthritis.” I was blank, staring.  I didn’t even know the questions to ask at the moment. In the four months prior, I hurt. The…
Read more
Newsletter Signup
Menu
Video not found
Video not found
Video not found
Video not found
Video not found
Video not found
Video not found
Video not found
Video not found
Video not found
Video not found
Get The Newsletter








Video not found
Video not found
Video not found
Video not found
Video not found
Video not found
Video not found
Video not found
Video not found
Order Vectra


Get The Newsletter








Video not found
Video not found
Video not found